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Background: Obesity is a risk factor for cancer incidence and survival, but data on patterns of weight change in cancer
survivors are scarce and few stratify by pre-diagnosis weight status. In two population-based cohorts of older adults, we
examined weight change in cancer survivors and cancer-free controls in relation to baseline weight status.
Methods: In the English Longitudinal Study of Ageing (ELSA) and the Health and Retirement Study (HRS), we identified
participants diagnosed with cancer who had pre- and post-diagnosis BMI data (ELSA n = 264; HRS n = 2553), and
cancer-free controls (ELSA n = 1538; HRS n = 4946). Repeated-measures ANOVAs tested three-way interactions by group
(cancer/control), time (pre-/post-diagnosis), and pre-diagnosis weight status (normal-weight/overweight/obese).
Results: Mean BMI change was −0.07 (SD = 2.22) in cancer survivors vs. +0.14 (SD = 1.11) in cancer-free controls in ELSA,
and −0.20 (SD = 2.84) vs. +0.11 (SD = 0.93) respectively in HRS. Three-way interactions were significant in both cohorts
(ELSA p = .015; HRS p < .001). In ELSA, mean BMI change in normal-weight cancer survivors was +0.19 (SD = 1.53)
compared with −0.33 (SD = 3.04) in obese survivors. In ELSA controls, the respective figures were +0.09 (SD = 0.81)
and +0.16 (SD = 1.50). In HRS, mean change in normal-weight cancer survivors was +0.07 (SD = 2.30) compared
with −0.72 (SD = 3.53) in obese survivors. In HRS controls, the respective figures were +0.003 (SD = 0.66) and +0.27
(SD = 1.27).
Conclusion: Over a four-year period, in two cohorts of older adults, cancer survivors lost weight relative to cancer-free
controls. However, cancer survivors who were obese pre-diagnosis were more likely to lose weight than healthy-weight
survivors or obese adults without a cancer diagnosis. Whether this was due to differences in clinical status or deliberate
lifestyle change triggered by the cancer diagnosis is not known. Further research is needed to establish why weight loss
occurs more frequently in cancer survivors who were obese at diagnosis, and whether this has favourable effects on
mortality.
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There is growing interest in the role of body weight in
cancer, both in terms of its effect on incidence and on
survival. Overweight and obesity are associated with in-
creased risk of a number of the most common cancers
[1,2]. A growing body of evidence also identifies obesity
as a risk factor for recurrence of the primary cancer,* Correspondence: j.wardle@ucl.ac.uk
1Health Behaviour Research Centre, Department of Epidemiology and Public
Health, University College London, London, UK
Full list of author information is available at the end of the article
© 2014 Jackson et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.second primary cancers, reduced treatment effectiveness,
treatment-related complications, and mortality [3-11].
Although a number of studies have described changes in
weight and other anthropometric markers in cancer pa-
tient populations [12-15], the majority do not compare
changes to cancer-free controls, making it impossible to
determine whether the changes reported are related to the
cancer diagnosis or reflect typical changes over time. Two
exceptions are the Norwegian Women and Cancer study,
which found BMI change over a six-year period from
pre- to post-diagnosis did not differ between women who
developed cancer (breast or colorectal) and those whol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and Health cohort, where women who were diagnosed
with breast cancer also had a BMI change similar to those
who remained cancer-free [17], although men in the same
cohort who were diagnosed with cancer experienced a re-
duction in BMI relative to controls [18].
While these studies offer valuable insight into weight
change following a cancer diagnosis, overall BMI changes
may disguise differential patterns of change by weight sta-
tus. Pre-diagnosis obesity could be associated with greater
risk of weight increase if any underlying propensity exac-
erbated responses to the psychological stress of a cancer
diagnosis, or amplified responses to pharmaceutical treat-
ments that have a known risk of weight gain. Consistent
with this, a recent study observed an association between
obesity risk gene (FTO) status and weight gain in women
diagnosed with breast cancer [19], although no control
data were available to determine whether the same pattern
was seen in normal ageing. Alternatively, a cancer diagno-
sis could act as a ‘teachable moment’ [20]; promoting
healthy lifestyle changes and resulting in more effective
weight control; one previous study found that patients
with a higher BMI were at lower risk of post-diagnosis
weight gain [19].
The present study was therefore designed to provide
benchmark data on weight change in cancer survivors
relative to cancer-free controls stratified by weight sta-
tus. Using prospective data from two large population-
based cohorts; one from the UK and one from the US,
we examined the impact of a cancer diagnosis on BMI
by pre-diagnosis weight status. Cancer-free participants
from the same cohorts over the same time periods con-
trolled for other causes of weight change.
Methods
Study populations and measures
The English Longitudinal Study of Ageing (ELSA) and
the Health and Retirement Study (HRS) are longitu-
dinal population-based studies of UK and US adults
aged ≥50 years. They have a degree of harmonisation in
their data collection protocols, and both record weight
status and major health events. Details on the cohorts and
sampling methods have been published elsewhere [21,22],
and participants gave full informed consent, with ethical
approval obtained from the relevant bodies. ELSA data are
publicly available at http://discover.ukdataservice.ac.uk
and HRS data are available at https://ssl.isr.umich.edu/hrs/
start.php.
English Longitudinal Study of Ageing
ELSA is a panel study recruited from households with one
or more members aged ≥50 years responding to the Health
Survey for England (HSE) in 1998, 1999, and 2001 (core
sample: N =12099), with ‘refreshment samples’ added fromadditional rounds of the HSE in 2006, 2008, and 2012.
They have been interviewed in biennial waves from 2002.
At each wave, participants do a computer-assisted personal
interview and complete self-administered questionnaires.
In alternate waves a nurse visits the home to carry out a
health examination that includes anthropometry. To date,
three health examinations have been conducted; in 2004
(wave 2), 2008 (wave 4), and 2012 (wave 6). Anthropomet-
ric data from these waves were used for the present ana-
lyses, with information on cancer diagnoses taken from
questionnaire data in waves 2–6.Health and Retirement Study
HRS is a cohort study of US adults born between 1931
and 1941, plus their spouses or partners regardless of age
(core sample: N =12652). Refreshment samples are added
every three waves (six years). Participants are interviewed
every two years, and the interviews include questions on
new cancer diagnoses as well as self-reported anthropo-
metric data. To match the time intervals (four years) for
which nurse-measured anthropometric data were available
for ELSA, we used anthropometric data from waves 2, 4,
6, 8, and 10 of HRS, and cancer diagnoses reported in
waves 2–10.
Age, sex, and household non-pension wealth (a sensi-
tive indicator of socioeconomic status in this age group)
were included as covariates in all analyses.Cancer and comparison groups
The cancer survivor group in the ELSA cohort comprised
all respondents who reported a new cancer diagnosis in
waves 3 to 6. In the HRS cohort it comprised all respon-
dents who reported a new cancer diagnosis in waves 3 to
10. A cancer diagnosis was defined as answering ‘yes’ to
the question: ‘Have you ever been told by a doctor or other
health professional that you had cancer or any other kind
of malignancy’. Individuals in either cohort reporting a
cancer diagnosis at waves 1 or 2 were excluded from the
analysis because of the absence of pre-diagnosis BMI data.
Likewise, participants from a refreshment cohort reporting
a cancer diagnosis on joining the study were excluded for
the same reason. The longer time period of data collection
in HRS resulted in larger samples with BMI data over the
two time points of cancer survival and controls.
Because the analyses involved BMI change, participants
were only included if they had anthropometric data avail-
able both pre-and post-diagnosis. In ELSA, the post-
diagnosis point was wave 4 for patients reporting a new
diagnosis in waves 3 or 4, and wave 6 for patients report-
ing a new diagnosis in waves 5 or 6. The respective pre-
diagnosis points were waves 2 and 4. In HRS we adopted a
matched approach so that the post-diagnosis point was
the first even-numbered wave at or after a new cancer
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tuted the pre-diagnosis point.
In both samples, the comparison group comprised all
individuals who had not received a cancer diagnosis in
any wave and for whom full anthropometric data were
available for the waves selected to match the pre- and
post-diagnosis points. We selected all participants with-
out a cancer diagnosis rather than a completely healthy
control group because it enabled us to determine the
specific additional influence of a cancer diagnosis inde-
pendent of other chronic diseases. To match the ‘pre-
diagnosis’ BMI, we used the mean of all possible pre-
diagnosis waves (waves 2 and 4 in ELSA, and waves 2, 4,
6, and 8 in HRS). The matched ‘post-diagnosis’ BMI in
the comparison sample was the mean of all possible
post-diagnosis waves (waves 4 and 6 in ELSA, and waves
4, 6, 8, and 10 in HRS); giving an average interval of four
years to match that of the cancer group’s pre- to post-
diagnosis interval.
Statistical analysis
Analyses were performed using SPSS version 20, with a
p value < .05 determining statistical significance. Data were
analysed separately for each cohort because participants
were drawn from different populations, there were differ-
ences in measures (e.g. objectively measured vs. self-
reported weight and height), and because it allowed us to
replicate findings in two independent samples. We used
repeated-measures analyses of variance (ANOVAs) in each
cohort to first examine the group-by-time interaction
(differential change in BMI between cancer and com-
parison groups), similar to other studies in the field that
have not examined the effect of pre-diagnosis weight
status. We then examined the three-way interaction be-
tween group (cancer vs. control), time (pre- vs. post-
diagnosis), and pre-diagnosis weight status (normal
weight: BMI <25 kg/m2, overweight: BMI 25–29.9 kg/m2,
obese: BMI ≥30 kg/m2) to test the hypothesis that the
BMI change would vary by weight status. All these ana-
lyses controlled for age, sex, and wealth at the pre-
diagnosis time point. Because previous studies indicated
potential sex differences in changes in BMI following a
cancer diagnosis, we repeated analyses stratified by sex
(controlling for age and wealth). We selected BMI, rather
than weight, as our outcome variable for consistency with
the previous literature, but we also ran all analyses on
weight as a sensitivity check.
Results
The analysed sample comprised participants who had
data on height and weight on at least two consecutive
even waves of data collection (four years apart), and
were cancer-free at the first time. A new diagnosis of
cancer during the study period (the ‘cancer survivorgroup’) occurred in 264 individuals in ELSA and 2553 in
HRS. The comparison group comprised 1538 individuals
in ELSA and 4946 in HRS who remained cancer-free.
Cancer diagnoses were spread evenly across waves. In
ELSA, 49% of the new diagnoses were at waves 3 or 4,
and 51% at waves 5 or 6. In HRS, 25% of new diagnoses
were at waves 3 or 4, 30% at waves 5 or 6, 22% at waves
7 or 8, and 23% at waves 9 or 10.
Baseline demographic and anthropometric characteris-
tics of the cancer and comparison groups in ELSA and
HRS are shown in Table 1. In both cohorts, the cancer
survivors were older (p < .001) and included a higher
proportion of men (ELSA p = .038, HRS p < .001) than
the comparison group. The groups did not differ signifi-
cantly by wealth in either cohort. The cancer survivors
in both cohorts were taller (p < .001) and heavier (ELSA
p = .035, HRS p < .001) than the comparison group, pri-
marily due to the higher proportion of men. Mean BMI
was significantly higher in the cancer survivors than the
comparison group in ELSA (p < .001) but did not differ be-
tween groups in HRS. The cancer survivors in ELSA were
more likely to be overweight or obese than the compari-
son group. The cancer survivors in HRS were less likely to
be normal weight and more likely to be underweight.
BMI decreased over time in the cancer survivors and in-
creased in the comparison group. From pre- to post-
diagnosis in ELSA, mean BMI change was −0.07 kg/m2
(SD = 2.22) in the cancer survivors and +0.14 kg/m2
(SD = 1.11) in the comparison group. In HRS, it
was −0.20 kg/m2 (SD = 2.84) in the cancer survivors
and +0.11 kg/m2 (SD = 0.93) in the comparison group.
Figure 1 presents mean BMI values (adjusted for age, sex,
and wealth) pre-diagnosis and post-diagnosis in the cancer
survivors and the comparison group in each cohort. The
group-by-time interaction, including the demographic
covariates, was significant in ELSA (p = .018) and HRS
(p < .001).
The three-way interaction between group, time, and
pre-diagnosis weight status was significant in both cohorts
(ELSA p = .015; HRS p < .001), with the cancer-control
differences in BMI change being greatest among those
who were obese pre-diagnosis. In ELSA, the mean BMI
change in cancer survivors who had been normal weight
pre-diagnosis was +0.19 kg/m2 (SD = 1.53), compared
with −0.03 kg/m2 (SD = 1.99) in survivors who had been
overweight, and −0.33 kg/m2 (SD =3.04) in those who had
been obese. In the ELSA comparison group the respect-
ive figures were +0.09 kg/m2 (SD = 0.81), +0.20 kg/m2
(SD = 1.18), and +0.16 kg/m2 (SD = 1.50) (Figure 2).
In HRS, the mean BMI change in the cancer survivors
who had been normal weight was +0.07 kg/m2 (SD = 2.30),
compared with −0.14 kg/m2 (SD = 2.69) in survivors who
had been overweight, and −0.72 kg/m2 (SD = 3.53) in those
who had been obese. In the HRS comparison group the
Table 1 Baseline characteristics of the cancer group and comparison group in the two cohorts – percentage (n),
mean (SD)
ELSA cohort HRS cohort
Cancer group Comparison group p Cancer group Comparison group p
(n = 264) (n = 1538) (n = 2553) (n = 4946)
Demographic characteristics
Age (years) 66.33 (8.36) 63.47 (7.95) <.001 67.24 (9.31) 64.08 (7.69) <.001
Sex
Male 51.1% (135) 38.6% (594) <.001 54.2% (1385) 36.8% (1819) <.001
Female 48.9% (129) 61.4% (944) - 45.8% (1168) 59.6% (2949) -
Wealth quintile
1 (lowest) 14.3% (37) 12.7% (194) .768 16.1% (412) 13.8% (660) .070
2 17.8% (46) 18.8% (288) - 18.3% (467) 19.3% (918) -
3 21.3% (55) 20.3% (311) - 21.8% (557) 21.2% (1009) -
4 19.4% (50) 22.5% (344) - 21.2% (542) 22.4% (1070) -
5 (highest) 27.1% (70) 25.7% (394) - 22.5% (575) 23.3% (1111) -
Anthropometric characteristics*
Weight (kg) 77.23 (14.64) 72.98 (15.04) <.001 79.86 (17.06) 77.73 (16.40) <.001
Height (cm) 166.44 (8.96) 165.17 (9.08) .035 170.71 (10.00) 168.15 (9.70) <.001
BMI (kg/m2) 27.87 (4.86) 26.71 (4.97) <.001 27.34 (5.16) 27.39 (4.84) .654
Weight status
Underweight 0.8% (2) 1.0% (15) <.001 1.6% (42) 0.5% (24) <.001
Normal weight 28.4% (75) 45.6% (702) - 32.6% (832) 33.5% (1658) -
Overweight 42.0% (111) 31.3% (481) - 40.7% (1038) 40.7% (2015) -
Obese 28.8% (76) 22.1% (340) - 25.1% (641) 25.3% (1249) -
*Based on measured data in ELSA and self-reported in HRS.
Where percentage (n) is given numbers may not sum to the total sample number, as some items were not answered by all participants. Valid percentages are
shown for ease of comparison between groups.
Figure 1 Mean BMI at baseline and follow-up in the cancer group and the comparison group in the two cohorts.
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Figure 2 Mean BMI at baseline and follow-up in the cancer group and the comparison group in the ELSA cohort by pre-diagnosis
weight status.
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kg/m2 (SD = 0.85), and +0.27 kg/m2 (SD = 1.27)
(Figure 3).
In analyses stratified by pre-diagnosis weight status, the
group-by-time interaction was not statistically significant
in normal weight participants in either cohort (ELSA
p = .346, HRS p = .287). It was significant in overweight
participants in HRS (p = .001) but not ELSA (p = .111),
and was significant in obese participants in both cohorts
(ELSA p = .041, HRS p < .001) (see Figures 2 and 3).
Sex-stratified analyses showed a significant three-way
interaction between group, time, and pre-diagnosis weight
status in women in ELSA (p = .021) and men and women
in HRS (ps < .001), but the interaction did not reach sig-
nificance in men in ELSA (p = .118). When we examined
differences in BMI change over time between the cancer
group and comparison group by sex and weight status
(Additional file 1), we observed no significant group by
time interaction in normal weight men or women in either
ELSA (men p = .540; women p = .724) or HRS (men
p = .493; women p = .462). Similarly, the group-by-time
interaction was not significant in overweight men or
women in ELSA (men p = .054; women p = .567) or over-
weight men in HRS (p = .103) – although in each group
there was a trend towards greater weight loss among those
who received a cancer diagnosis than those who did
not – however, it was highly significant in HRS women
(p < .001). Among obese participants, the group-by-time
interaction was significant in women in ELSA (p = .013)
and men and women in HRS (ps < .001), but was not sig-
nificant in ELSA men (p = .557). We reran all analyseswith weight as the outcome variable and observed no
notable differences in the results.
Discussion
This study used prospective data from population-based
samples of older adults in the UK and the US to exam-
ine the effect of a cancer diagnosis on BMI in relation to
pre-diagnosis weight status. In both samples, obese indi-
viduals who received a cancer diagnosis experienced a
small but significant reduction in BMI from pre- to
post-diagnosis, while there was little change in BMI in
obese individuals who remained cancer-free. In contrast,
among normal weight individuals in both samples, there
was no differential BMI change related to a cancer diag-
nosis. Among the overweight, the pattern was similar to
the obese (greater weight loss in those who got a cancer
diagnosis) which was significant in HRS, but not signifi-
cant in the smaller ELSA sample.
Two previous studies had found no significant differ-
ences between women who received a breast cancer diag-
nosis and those who remained cancer-free [16,17], but
they did not test the interaction with pre-diagnosis weight
status. A third study that compared change in BMI among
men diagnosed with any cancer with cancer-free controls
found that a cancer diagnosis was associated with a signifi-
cant reduction in BMI, but again did not examine differ-
ences by pre-diagnosis weight status [18]. In the present
study, the pattern of results did not differ by sex in the
HRS cohort, with significant differences between obese
cancer cases and obese controls in BMI change over time,
but no difference between normal weight groups. We saw
Figure 3 Mean BMI at baseline and follow-up in the cancer group and the comparison group in the HRS cohort by pre-diagnosis
weight status.
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no significant differences in BMI change over time in any
weight group in men in ELSA.
We did not have data on whether weight loss was
intentional, but the fact that the reduction in BMI was
not observed in cancer survivors with a healthy BMI,
but was seen among those who had been obese pre-
diagnosis, suggests that it may have been at least partly
intentional. There have been few investigations of cancer
survivors’ beliefs about weight loss, but a recent survey
of 200 breast cancer survivors indicated widespread be-
lief that weight loss is beneficial, with 70% believing that
limiting food intake to maintain or lose weight could re-
duce the risk of recurrence [23]. Deliberate attempts to
lose weight were also common in the breast cancer sam-
ple, with 65% having limited their intake during the last
month to this end [23]. In another study, 87% of cancer
survivors thought that advice on weight loss for cancer
patients would be beneficial and the same number
thought it was doctors’ duty to provide such advice [24].
That we saw a stronger impact of a cancer diagnosis on
weight change in women than men in the ELSA cohort
also points to weight loss being intentional, given that
obese women tend to be more likely than obese men to
recognise that they are too heavy [25], and more likely
to report trying to lose weight [25].
However, an alternative explanation for the observed
interaction with weight status is that obese cancer survi-
vors had more advanced cancers than the normal weight
survivors, and their greater weight loss was a conse-
quence of this. Several studies suggest that obese indi-
viduals are less likely to participate in age-appropriatecancer screening programmes [26-29], and studies in
breast cancer populations have identified obesity as a
risk factor for patient delay (time from onset of first
symptoms to first consultation of a doctor) [30], and ad-
vanced stage at diagnosis [31,32]. Because weight loss is
a common feature in advanced cancers, affecting be-
tween 39% and 82% of patients [33], if the obese cancer
survivors in our sample had more advanced disease than
the normal weight survivors, this could explain the dif-
ferential BMI change.
The present findings showing weight loss occurring in
individuals who receive a cancer diagnosis highlight the
importance of future research to clarify whether weight
loss is a deliberate health promoting activity or is a more
ominous sign of underlying health state. Understanding
the implications of weight loss among obese individuals
who receive a cancer diagnosis is important for tailoring
lifestyle advice and/or identifying those at higher risk of
mortality. Future work not only needs information on
cancer site, but also on disease stage.
The consequences of weight loss for cancer survivors is a
crucial issue in survivorship research. Observational studies
have demonstrated associations between weight loss and
increased risk of recurrence and higher all-cause mortality
in several large cohorts of breast cancer survivors [34-36],
with similar adverse effects reported in smaller samples of
colorectal and endometrial cancer survivors [37,38]. In one
study [34], associations between weight loss and mortality
were stratified by weight status, and there was no evidence
that weight loss was less harmful in the obese, although like
the present study, there was no information on whether
or not the weight loss was intentional. In non-cancer
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mortality, whereas intentional weight loss has an overall
neutral effect on survival [39]. Intervention trials offer bet-
ter insight into the consequences of intentional weight loss,
but no trials to date have directly investigated the effect on
survival, although a study looking at the impact of weight
loss on breast cancer recurrence and survival is underway
[40]. However, comparison of the results of two large inter-
vention studies of dietary change in breast cancer survivors
(the Women’s Intervention Nutrition Study (WINS) [41]
and the Women’s Healthy Eating and Lifestyle (WHEL)
study [42]) suggests that diet-induced weight loss might
have a favourable effect on recurrence. Both studies
achieved positive changes in diet in the intervention group,
but only WINS achieved significant weight loss, and only in
WINS were recurrence rates lower in the intervention
group. Further evidence for potential benefits of weight loss
comes from small randomised controlled trials of over-
weight and obese breast cancer survivors which have
examined cancer-related biomarkers. In the Breast Cancer
Survivors Health and Physical Exercise (SHAPE) trial, post-
menopausal survivors who lost at least 5% of their body
weight had lower levels of oestrone, oestradiol, and bio-
available oestradiol than women who did not achieve the
same weight loss [43]. In another trial there were favourable
changes in sex hormone-binding globulin, leptin, high-
sensitivity C-reactive protein, and total cholesterol in
women who lost at least a kilogram in weight [44]. Given
that these biomarkers have been associated with cancer re-
currence and progression [45,46], the results suggest that
intentional weight loss may lead to improved outcomes in
breast cancer survivors. However, evidence of poorer out-
comes associated with weight loss in the larger observa-
tional studies, alongside modest evidence for improved
outcomes with intentional weight loss, underscores the
need for research into the determinants and consequences
of weight loss following a cancer diagnosis.
The present study had some strengths. It is one of only
a few studies to examine change in BMI from pre-
diagnosis to post-diagnosis using a prospective design,
thus minimising the potential for reporting bias. It also
included cancer-free controls in order to distinguish
changes related to a cancer diagnosis from those occur-
ring naturally with age in the population. Finding the
same pattern of results in two independent cohorts at-
tests to the robustness of the effect. The availability of
objective measurements of height and weight in ELSA is
an advantage because all the previous controlled longitu-
dinal studies have relied on self-reported data on at least
one time point [16-18].
However, there were also a number of limitations.
Cancer data were self-reported, but this may not be too
problematic given previous studies have shown high
agreement between self-reported cancer diagnoses andmedical record validation in population-based samples
[47-49]. We do not have information on the exact date
of diagnosis, which could have been any time from just
after the last wave at which the participant reported not
having a cancer diagnosis, until just before the wave at
which a cancer diagnosis was first reported; a range of
two years. We also have no available data on stage at
diagnosis, nor on weight loss intentions, and so it was
not possible to test whether the interaction with weight
status was a consequence of obese participants being
more likely to be diagnosed at an advanced stage, or of
making intentional efforts to reduce BMI [31,32]. The
study was not powered to analyse changes by cancer site,
and given the substantial heterogeneity across cancers it
is likely that results would differ by site. In order to
study change in BMI over time, our analyses were lim-
ited to participants with data on at least two consecutive
waves with nurse measurements available in ELSA (four
years apart) and at the same intervals in HRS. Partici-
pants who died, dropped out, did not answer the cancer
diagnosis question, or did not have data on BMI were
therefore not included. The analysed samples were slightly
younger and wealthier than the total ELSA and HRS sam-
ples, in line with retention in other longitudinal studies
[50], so results may not be population-representative. In
addition, the cancer group was necessarily restricted to
those who were still alive at follow-up and sufficiently well
enough to participate, so the results cannot be generalised
to cases with more aggressive cancers.
Conclusions
In conclusion, in large samples from two countries, we
found that BMI decreased more following a cancer diag-
nosis in individuals who were obese beforehand than
those who had been normal weight before diagnosis; but
no such difference was observed over the same time
period in cancer-free controls. With observational evi-
dence suggesting that weight loss is associated with
poorer outcomes for cancer survivors, but emerging trial
evidence indicating there may be benefits of intentional
weight loss for those who are overweight or obese, it is
vital to get a better understanding of the determinants
and consequences of weight loss following a cancer diag-
nosis to understand its full clinical implications. Clinical
populations could extend the present findings by offer-
ing insight into differences in change in BMI by cancer
site, stage at diagnosis, time since diagnosis, and treat-
ment method.
Additional file
Additional file 1: Mean (SD) changes in BMI (kg/m2) over time in the
cancer group and comparison group in the two cohorts, and p values
for the group by time interaction, by sex and weight status.
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